Dogwood Announces $5 Million Private Placement with CK Life Sciences Int’l., (Holdings) Inc.
Dogwood Therapeutics announced a $5 million private placement from a subsidiary of its largest shareholder, CK Life Sciences, at $1.22 per share — 4,098,360 shares with no warrants or derivatives, priced at-the-market under Nasdaq rules. Proceeds fund Phase 3 preparatory activities for Halneuron® in chemotherapy-induced neuropathic pain and extend the operational runway through March 2027. The financing lands weeks before topline HAL-CINP Phase 2b data (239 patients, ~25 U.S.
Key figures
- Drug Name
- Halneuron®
- Deal Value Usd
- 5000000
- Phase Of Trial
- Phase 2b
- Offering Price
- 1.22
- Shares Offered
- 4098360
- Trial sites
- approximately 25 sites in the U.S.
- Trial patients
- 239
- Runway extension
- operational runway through March 2027
- Topline data timing
- November 2026
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.